-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present , the first-line standard treatment for advanced non-small cell lung cancer ( NSCLC ) with negative driver genes is immunotherapy monotherapy or combination chemotherapy
.
Immune checkpoint inhibitors (ICIs) include PD1 and PD-L1 inhibitors
At present , the first-line standard treatment for advanced non-small cell lung cancer ( NSCLC ) with negative driver genes is immunotherapy monotherapy or combination chemotherapy
The study included 23 patients, 3 patients (13.
0%) who had previously received combined immunotherapy (CPI)
.
The overall safety population for NSCLC includes 23 patients
The study included 23 patients, 3 patients (13.
A total of 204 adverse events (AEs) were reported in 22 patients (95.
Adverse events
Adverse eventsIn the overall population, 6 patients were confirmed as responders, with an ORR of 26.
1%
.
Five responders (25.
In the overall population, 6 patients were confirmed as responders, with an ORR of 26.
The median survival follow-up time of NSCLC patients who have not received CPI treatment in the past was 39.
Curative effect
Curative effectThe median survival follow-up of NSCLC patients who received CPI treatment was 39.
0 months (3.
3-39.
0 months); 3 patients (100%) had PFS events, and 2 patients (66.
7%) died
.
The median progression-free survival was 2.
The median survival follow-up of NSCLC patients who received CPI treatment was 39.
In summary, studies have shown that Atezolizumab combined with ipilimumab has shown certain efficacy in the treatment of treated advanced non-small cell lung cancer with negative driver genes, and the toxicity is controllable
Original source:
Wong DJ, Bauer TM, Gordon MS, et al.
Wong DJ, Bauer TM, Gordon MS, et al.
Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial.
Clin Lung Cancer.
2021 Jul 20:S1525-7304 (21)00183-2.
doi: 10.
1016/j.
cllc.
2021.
07.
002.
Epub ahead of print.
PMID: 34456145.
Leave a message here
